Acumen's acu193, an anti-amyloid beta oligomer antibody, granted fda fast track designation for alzheimer's disease

Charlottesville, va. and carmel, ind., oct. 24, 2022 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) today announced that acu193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (aΒos), has been granted fast track designation for the treatment of early alzheimer's disease by the u.s. food and drug administration (fda). acu193 is currently being studied in the phase 1 intercept-ad trial designed to assess safety and proof of mechanism of acu193.
ABOS Ratings Summary
ABOS Quant Ranking